- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
Jun 18, 2013 | 03:37 PM EDT
We'll return to a pharma holding and fund the purchase with two sales. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
Jun 18, 2013 | 01:07 PM EDT
This week, David Peltier answers questions about two model portfolio names and two other specific low-dollar stocks. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
Jun 17, 2013 | 04:33 PM EDT
Amid churning market action this week, we added a new model portfolio position, closed another and trimmed one large holding. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Alexion Pharmaceuticals Inc. (ALXN)
ALXN (NASDAQ:Drugs)
$92.39
+1.07
+1.17%
Today's Range: 91.35 - 93.58 |
ALXN Avg Daily Volume: 1,478,800
| Last Update: 06/18/13 - 4:00 PM EDT |
| Volume: 937,680 |
| YTD Performance: -2.58% |
| Open: $91.47 |
| Previous Close: $91.32 |
| 52 Week Range: $81.82 - $119.54 |
| Oustanding Shares: 195,146,634 |
| Market Cap: 17,996,422,587 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 15 | 14 | 14 | 15 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.42 | 1.45 | 1.45 | 1.42 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.60 | $0.70 | $2.67 | $3.01 |
| Number of Analysts | 4 | 4 | 4 | 4 |
| High Estimate | $0.62 | $0.72 | $2.71 | $3.16 |
| Low Estimate | $0.58 | $0.67 | $2.60 | $2.86 |
| Prior Year | $0.41 | $0.53 | $1.86 | $2.67 |
| Growth Rate (Year over Year) | 46.34% | 32.55% | 43.41% | 12.65% |
Alexion rated new Neutral at Credit Suisse
Coverage of ALXN was started with a Neutral rating, Credit Suisse said. $110 price target. Company lacks near-term catalysts.
We see a lot of short squeezes as money rotates into laggard groups.
Just a natural change in leadership.
Alexion Pharma price target and estimates increased at UBS
ALXN estimates were increased to reflect increased confidence in manufacturing now that the source of contamination has been identified. Price target goes to $123.
Upward momentum is lagging.
Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken
Alexion Pharmaceuticals numbers cut at UBS
Shares of ALXN now seen reaching $120, UBS said. Estimates also lowerd on FDA warning letter and EU updates. Buy rating.
Charts of Actavis and Alexion show a combination of positive technical factors.
Alexion downgraded at Lazard
ALXN was downgraded from Buy to Neutral, Lazard Capital Markets said. $102 price target. Stock appears attractive, following a 30% decline.
Alexion Pharmaceuticals numbers lowered at Jefferies
Shares of ALXN now seen reaching $88, Jefferies said. Estimates also lowered on delay in Soliris launch. Hold rating.
Real Money Pro Quick Links
Our Tweets
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.